Second-generation tyrosine kinase inhibitors: the first-line treatment strategy of chronic myeloid leukemia patients?.
10.3760/cma.j.issn.0253-2727.2014.12.001
- Author:
Qian JIANG
1
Author Information
1. Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
Protein Kinase Inhibitors;
Protein-Tyrosine Kinases
- From:
Chinese Journal of Hematology
2014;35(12):1049-1052
- CountryChina
- Language:Chinese
